Peptides
Retatrutide
What is it?
Retatrutide is an investigational drug that activates three hormone receptors: GLP-1, GIP, and glucagon. It is being developed for obesity and related conditions. It is not an FDA-approved product as of this review. [1,2]
How does it work?
GLP-1 and GIP signaling can reduce appetite and improve glucose regulation. Glucagon-receptor activity may add another pathway affecting energy balance. The combined effect is tested in people rather than inferred from the three names alone. [1]
What have weight-loss studies found?
In a randomized, double-blind phase 2 study of 338 adults with obesity or overweight plus a related condition, the 12 mg group lost an average 24.2% of starting body weight over 48 weeks, compared with 2.1% on placebo. Lower-dose groups also lost more than placebo. Nausea and other gastrointestinal effects were common, especially during dose escalation. The trial was sponsor funded and was not designed to identify a final prescribing schedule. [1]
A peer-reviewed phase 3 trial of 2,339 adults without diabetes reported 25.0% average weight loss at 80 weeks with 12 mg once weekly, versus 3.9% with placebo, in the treatment-regimen analysis. That trial also used once-weekly injections, so it does not answer whether splitting the same weekly amount changes results or side effects. [2]
What should you know before considering it?
Retatrutide remains investigational. A peptide sold online under that name is not the same as receiving the studied product in a monitored trial. Medical screening and side-effect management matter with this drug class. [1,2]
STUDIED TRIAL RANGE
How much?
Studied as one injection per week in a monitored trial.
CAMERON’S PRACTICAL PREFERENCE
Split dosing
2–3 injections per week
Divide the same weekly total across those days.
No approved dose. Split dosing has not been compared in a controlled trial.
The phase 2 trial used 1, 4, 8, and 12 mg arms with dose escalation. Cameron reports a smoother week when splitting the same total; Hunter Williams and Jay Campbell describe similar practices. Split dosing has not been compared with once-weekly dosing in a controlled retatrutide trial. [1,3,4]
Read detailed dosing notes
1–12 mg once weekly — the range of retatrutide arms studied in the 48-week phase 2 trial, with specified starting doses and escalation. The 12 mg arm was not a starting dose, and the study's largest arm is not a self-use recommendation. [1]
Split dosing is my practical preference: I divide the same weekly total into two or three injections on separate days, without increasing the weekly amount. In my experience, and among people I know who use retatrutide or other GLP-1 medicines, the effect feels smoother through the week. Hunter Williams recommends considering a split when once-weekly peaks are troublesome; Jay Campbell also describes dividing his retatrutide use across three days. [3,4]
Retatrutide trials have used once-weekly injections. No controlled retatrutide trial has compared that schedule with split dosing for weight loss or side effects, so the smoother experience remains a reported practice rather than a proven clinical advantage. [1,3]
There is no FDA-approved retatrutide dose; only a qualified trial team can apply an investigational protocol. [2]
Sources & further reading
- Jastreboff et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial (opens in a new tab)www.nejm.org
- TRIUMPH-1 investigators (2026). Retatrutide, a triple hormone receptor agonist, for treatment of obesity (opens in a new tab)pubmed.ncbi.nlm.nih.gov
- Hunter Williams (2026). Retatrutide Masterclass: once weekly versus split dosing (opens in a new tab)library.hunterwilliamshealth.com
- Jay Campbell (2025). Retatrutide, Part 2: The power of microdosing retatrutide (opens in a new tab)jaycampbell.com